Status:
ACTIVE_NOT_RECRUITING
Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions:
Primary Hemophagocytic Lymphohistiocytosis
Eligibility:
All Genders
1-18 years
Brief Summary
The goal of this retrospective study is to assess efficacy and safety of emapalumab prescribed for the treatment in children with refractory from of pHLH.
Detailed Description
Primary hemophagocytic lymphohistiocytosis (pHLH) encompasses a group of genetically determined disorders, characterized by severe, often fulminant systemic inflammation, cytopenia and multiple organ ...
Eligibility Criteria
Inclusion
- Criteria for inclusion in the study were:
- age from 0 to 18 y.
- the diagnosis of pHLH ( established according to the Histiocytic society criteria).
- treatment with empalumab for at least 2 weeks
- signed informed consent for participation in the study
Exclusion
- not applicable. signed informed consent for participation in the study
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06587191
Start Date
August 1 2024
End Date
October 1 2024
Last Update
October 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of Pediatric Hematology, Oncology and Immunology
Moscow, Russia